Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA. [PDF]
Caviglia GP +17 more
europepmc +1 more source
Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma. [PDF]
Wu M, Yu H, Pang S, Liu A, Liu J.
europepmc +1 more source
Correction: Guarneri et al. Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma. <i>Cancers</i> 2025, <i>17</i>, 167. [PDF]
Guarneri V +13 more
europepmc +1 more source
Identification of serum tsRNA-Thr-5-0015 and combined with AFP and PIVKA-II as novel biomarkers for hepatocellular carcinoma. [PDF]
Jin K +9 more
europepmc +1 more source
Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection. [PDF]
Qiu ZC +8 more
europepmc +1 more source
Alpha-fetoprotein-to-PIVKA-II ratio as a potential biomarker for hepatocellular carcinoma differentiation, imaging characteristics, and patient survival. [PDF]
Dieu-Merci MN +9 more
europepmc +1 more source
Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. [PDF]
Jin Y, Xu A.
europepmc +1 more source
Prognostic significance of postoperative serological incomplete conversion of AFP and PIVKA-II after hepatic resection for hepatocellular carcinoma: a multicenter analysis of 1755 patients. [PDF]
Wang M +17 more
europepmc +1 more source
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma. [PDF]
Kudo M.
europepmc +1 more source

